Zoetis (NYSE:ZTS) issued its quarterly earnings data on Thursday. The company reported $0.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.06, Briefing.com reports. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.58 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.83 EPS. Zoetis updated its FY19 guidance to $3.57-3.62 EPS.
NYSE ZTS traded down $3.17 during mid-day trading on Friday, reaching $117.86. 3,818,712 shares of the stock were exchanged, compared to its average volume of 2,125,332. Zoetis has a one year low of $78.90 and a one year high of $130.20. The stock has a 50 day simple moving average of $125.46 and a 200-day simple moving average of $116.48. The stock has a market cap of $57.43 billion, a P/E ratio of 37.65, a P/E/G ratio of 2.98 and a beta of 0.88. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend is Monday, October 21st. Zoetis’s dividend payout ratio is presently 21.09%.
In related news, EVP Roxanne Lagano sold 4,463 shares of Zoetis stock in a transaction on Monday, August 19th. The shares were sold at an average price of $125.99, for a total transaction of $562,293.37. Following the completion of the transaction, the executive vice president now owns 33,190 shares of the company’s stock, valued at $4,181,608.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction on Monday, September 16th. The stock was sold at an average price of $120.05, for a total transaction of $735,066.15. Following the transaction, the executive vice president now directly owns 41,698 shares of the company’s stock, valued at approximately $5,005,844.90. The disclosure for this sale can be found here. Insiders have sold 34,332 shares of company stock valued at $4,258,182 in the last three months. 0.29% of the stock is owned by insiders.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.